Novelia®, published on CDE (Center for Drug Evaluation) platform in China!
The Center for Drug Evaluation (CDE) performs regulatory evaluation of new drugs and medical devices to assess if these can be brought to the market in China. Our multi-dose eye dropper, Novelia®’s publication on CDE platform means that our delivery system can be referenced through its packaging system DMF number in Drug Product Application in China. With this first milestone achieved, our dossier is now available through a letter of authorization. The pharmaceutical companies can now submit their documentation for the evaluation of their drug products with Novelia® through a letter of authorization.
China, a land of opportunities for ophthalmics.
Ophthalmic pathologies such as myopia, cataract and glaucoma are on the increase around the country (source). It is hence critical to offer treatment solutions to people suffering from these pathologies.
Novelia® is a multi-dose eye dropper system which avoids the need for preservatives in the drug. It prevents bacterial contamination over the duration of treatment through its patented PureFlow® Technology.
0% preservatives, 100% eye protection. It is already available in Europe, Latin America, North America, Oceania, Middle East and Asia Pacific with more than 240 references in OTC and Rx.